AbbVie Inc. (NYSE:ABBV) Is Largely Controlled by Institutional Shareholders Who Own 73% of the Company
AbbVie Hits 4-week High
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $224
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com
AbbVie (ABBV) Upgraded to Buy: What Does It Mean for the Stock?
Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet
Is AbbVie Inc. (ABBV) the Best Pharma Dividend Stock to Buy In 2024?
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Global enterprises are "fully powered" to borrow money! The scale will reach 8 trillion dollars in 2024, setting a record.
Bankers stated that low financing costs were the initial reason for companies to choose to issue Bonds early, as they wanted to avoid the market volatility risks that could arise around the USA elections. However, after Trump's election victory, the market's credit spreads further narrowed, prompting some companies to decide to lock in their borrowing needs for the following year in order to secure funds under favorable market conditions.
Express News | In 2024, Global corporate borrowing surged to a record 8 trillion US dollars.
AbbVie's (NYSE:ABBV) Five-year Earnings Growth Trails the 20% YoY Shareholder Returns
Achievements and Progress Heading Into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Looking Into AbbVie's Recent Short Interest
AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Schwab US Dividend Equity ETF Reverses In December: What's Going On?